NCT02545075 - A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine | Biotech Hunter

Enrollment

182

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

April 19, 2019

Study Completion Date

April 19, 2019

Conditions

Melanoma

Interventions

DRUG

Ipilimumab

DRUG

Dacarbazine

Trial Locations (8)

Local Institution, Beijing

Local Institution, Changchun

Local Institution, Shanghai

Local Institution, Nanjing

Local Institution, Tianjin

Local Institution, Xi’an

Local Institution, Hanghzou

Local Institution, Kunming